Axsome Therapeutics, Inc.
AXSM
$118.51
$1.371.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 150.04M | 121.46M | 118.77M | 104.76M | 87.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 150.04M | 121.46M | 118.77M | 104.76M | 87.17M |
| Cost of Revenue | 13.45M | 9.79M | 10.51M | 8.44M | 8.06M |
| Gross Profit | 136.59M | 111.67M | 108.25M | 96.33M | 79.11M |
| SG&A Expenses | 130.28M | 120.79M | 113.27M | 95.56M | 103.55M |
| Depreciation & Amortization | 1.59M | 1.57M | 1.61M | 1.61M | 1.59M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 194.86M | 176.93M | 180.40M | 151.00M | 163.05M |
| Operating Income | -44.82M | -55.47M | -61.63M | -46.23M | -75.89M |
| Income Before Tax | -48.93M | -59.41M | -74.83M | -64.60M | -79.35M |
| Income Tax Expenses | -960.00K | -- | 85.00K | -- | -- |
| Earnings from Continuing Operations | -47.97M | -59.41M | -74.91M | -64.60M | -79.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.97M | -59.41M | -74.91M | -64.60M | -79.35M |
| EBIT | -44.82M | -55.47M | -61.63M | -46.23M | -75.89M |
| EBITDA | -42.57M | -53.34M | -59.56M | -44.17M | -73.89M |
| EPS Basic | -0.97 | -1.22 | -1.54 | -1.34 | -1.67 |
| Normalized Basic EPS | -0.59 | -0.74 | -0.82 | -0.63 | -1.01 |
| EPS Diluted | -0.97 | -1.22 | -1.54 | -1.34 | -1.67 |
| Normalized Diluted EPS | -0.59 | -0.74 | -0.82 | -0.63 | -1.01 |
| Average Basic Shares Outstanding | 49.44M | 48.87M | 48.54M | 48.14M | 47.57M |
| Average Diluted Shares Outstanding | 49.44M | 48.87M | 48.54M | 48.14M | 47.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |